[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fD0qI3e8689p7f0cGqwpzPgptkIt7pLUBNHBGC_aCg44":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Xiangya Hospital of Central South University",[4],154,false,60,8,819509,26,95,[14,17,20,22,25,27,29,32],{"name":15,"count":16},"Parkinson Disease",7,{"name":18,"count":19},"Sepsis",5,{"name":21,"count":19},"Obesity",{"name":23,"count":24},"Hepatocellular Carcinoma",3,{"name":26,"count":24},"Traumatic Brain Injury",{"name":28,"count":24},"Nasopharyngeal Carcinoma",{"name":30,"count":31},"Osteoarthritis, Knee",2,{"name":33,"count":31},"Breast Neoplasms",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06399926","Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir","2025-06-30","Pemetrexed",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06704685","A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI","2025-10-01","Butylphthalide",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06866977","A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer","2025-10-31","Oncolytic virus VRT106",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05751733","Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST","2026-01-01","Apatinib Mesylate",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06663254","Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery","2026-03-30","Hydroxyethyl starch 130\u002F0.4",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06530563","the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery","2026-04","Oliceridine Injection [Olinvyk]",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07412223","Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery","2026-12-01","Tegileridine",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06882876","JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study","2027-01-01","JS014 Combined With Toripalimab and TACE",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07235995","Paracetamol and Mannitol Injection and Postoperative Delirium","2027-01-31","Acetaminophen group",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06746701","Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.","2027-05-25","Peg-IFNα-2b combined with NA",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,132,150,177,195,219,237,262,280,304,322,348,370,388,415,433,467,485,513,536,559,577,603,625,648,666,691,730,759,797,819,844,862,880,898,923,941,969,987,1005,1023,1048,1074,1092,1153,1179,1197,1215,1233,1251,1278,1296,1314,1348,1374,1400,1425,1443,1468,1494,1518,1542,1560,1586,1604,1627,1654,1672,1690,1708,1732,1758,1776,1794,1812,1836,1861,1886,1904,1928,1955,1973,2003,2021,2047,2065,2090,2113],{"intervention":94,"totalTrials":31,"cells":95},"Morphine",{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":130},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":129,"soonestReadout":68},[107,119],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT02135055","Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status","UNKNOWN",[90],"2015-03","2014-05",80,[116,18],"Inflammatory Disorder of Immune System",[118,94],"Midazolam",{"nctId":66,"briefTitle":67,"status":120,"phases":121,"primaryCompletion":68,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":128},"NOT_YET_RECRUITING",[90],"2027-02-24","2026-02-24",152,[126,127],"Pain, Postoperative","Postoperative Ileus",[69,94],1,{"trials":131,"activeCount":98},[],{"intervention":69,"totalTrials":129,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":148},{"trials":135,"activeCount":98},[],{"trials":137,"activeCount":98},[],{"trials":139,"activeCount":98},[],{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":129,"soonestReadout":68},[144],{"nctId":66,"briefTitle":67,"status":120,"phases":145,"primaryCompletion":68,"completion":122,"start":123,"enrollment":124,"conditions":146,"interventions":147},[90],[126,127],[69,94],{"trials":149,"activeCount":98},[],{"intervention":151,"totalTrials":129,"cells":152},"vunakizumab and recaticimab.",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":175},{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":98},[],{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"trials":162,"activeCount":129,"soonestReadout":167},[163],{"nctId":164,"briefTitle":165,"status":120,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT07373847","Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia",[90],"2027-06-30","2027-08-30","2026-01-20",40,[172],"Plaque Psoriasis",[151,174],"vunakizumab and placebo",{"trials":176,"activeCount":98},[],{"intervention":174,"totalTrials":129,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":193},{"trials":180,"activeCount":98},[],{"trials":182,"activeCount":98},[],{"trials":184,"activeCount":98},[],{"trials":186,"activeCount":98},[],{"trials":188,"activeCount":129,"soonestReadout":167},[189],{"nctId":164,"briefTitle":165,"status":120,"phases":190,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":191,"interventions":192},[90],[172],[151,174],{"trials":194,"activeCount":98},[],{"intervention":59,"totalTrials":129,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":217},{"trials":198,"activeCount":98},[],{"trials":200,"activeCount":98},[],{"trials":202,"activeCount":98},[],{"trials":204,"activeCount":98},[],{"trials":206,"activeCount":129,"soonestReadout":58},[207],{"nctId":56,"briefTitle":57,"status":120,"phases":208,"primaryCompletion":58,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":215},[90],"2026-08-30","2024-11-30",410,[213,214],"Perioperative Volume Replacement","Hydroxyethyl Starch",[59,216],"Sodium acetate Ringer",{"trials":218,"activeCount":98},[],{"intervention":216,"totalTrials":129,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":235},{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":98},[],{"trials":228,"activeCount":98},[],{"trials":230,"activeCount":129,"soonestReadout":58},[231],{"nctId":56,"briefTitle":57,"status":120,"phases":232,"primaryCompletion":58,"completion":209,"start":210,"enrollment":211,"conditions":233,"interventions":234},[90],[213,214],[59,216],{"trials":236,"activeCount":98},[],{"intervention":79,"totalTrials":129,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":247,"NA":260},{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"trials":244,"activeCount":98},[],{"trials":246,"activeCount":98},[],{"trials":248,"activeCount":129,"soonestReadout":78},[249],{"nctId":76,"briefTitle":77,"status":120,"phases":250,"primaryCompletion":78,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":258},[90],"2027-04-30","2025-12-01",1092,[255,256,257],"Postoperative Delirium","Elderly","Non Cardiac Surgery",[79,259],"Sufentanil group",{"trials":261,"activeCount":98},[],{"intervention":259,"totalTrials":129,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":278},{"trials":265,"activeCount":98},[],{"trials":267,"activeCount":98},[],{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":129,"soonestReadout":78},[274],{"nctId":76,"briefTitle":77,"status":120,"phases":275,"primaryCompletion":78,"completion":251,"start":252,"enrollment":253,"conditions":276,"interventions":277},[90],[255,256,257],[79,259],{"trials":279,"activeCount":98},[],{"intervention":64,"totalTrials":129,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":302},{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":98},[],{"trials":287,"activeCount":98},[],{"trials":289,"activeCount":98},[],{"trials":291,"activeCount":129,"soonestReadout":63},[292],{"nctId":61,"briefTitle":62,"status":120,"phases":293,"primaryCompletion":63,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":300},[90],"2026-05","2025-08",606,[298,299],"Acute Pain","Opioid Analgesic Adverse Reaction",[64,301],"Sufentanil Citrate",{"trials":303,"activeCount":98},[],{"intervention":301,"totalTrials":129,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":314,"NA":320},{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"trials":313,"activeCount":98},[],{"trials":315,"activeCount":129,"soonestReadout":63},[316],{"nctId":61,"briefTitle":62,"status":120,"phases":317,"primaryCompletion":63,"completion":294,"start":295,"enrollment":296,"conditions":318,"interventions":319},[90],[298,299],[64,301],{"trials":321,"activeCount":98},[],{"intervention":323,"totalTrials":129,"cells":324},"Different doses of Metoprolol.",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":346},{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":98},[],{"trials":332,"activeCount":98},[],{"trials":334,"activeCount":129,"soonestReadout":339},[335],{"nctId":336,"briefTitle":337,"status":120,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":345},"NCT06825728","Metoprolol in Patients With HFrEF and COPD",[90],"2028-02","2025-02",311,[343,344],"Heart Failure With Reduced Ejection Fraction (HFrEF)","COPD (Chronic Obstructive Pulmonary Disease)",[323],{"trials":347,"activeCount":98},[],{"intervention":44,"totalTrials":129,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":366,"NA":368},{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":98},[],{"trials":355,"activeCount":98},[],{"trials":357,"activeCount":129,"soonestReadout":43},[358],{"nctId":41,"briefTitle":42,"status":120,"phases":359,"primaryCompletion":43,"completion":360,"start":361,"enrollment":170,"conditions":362,"interventions":364},[89],"2025-12-31","2024-12-01",[363],"ST-segment Elevation Myocardial Infarction (STEMI)",[44,365],"Butylphthalide placebo",{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":98},[],{"intervention":365,"totalTrials":129,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":384,"NA":386},{"trials":373,"activeCount":98},[],{"trials":375,"activeCount":98},[],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":129,"soonestReadout":43},[380],{"nctId":41,"briefTitle":42,"status":120,"phases":381,"primaryCompletion":43,"completion":360,"start":361,"enrollment":170,"conditions":382,"interventions":383},[89],[363],[44,365],{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":98},[],{"intervention":389,"totalTrials":129,"cells":390},"Combination Group",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":411,"NA":413},{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":129,"soonestReadout":403},[399],{"nctId":400,"briefTitle":401,"status":120,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":409},"NCT07369999","Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke",[89],"2029-03-01","2029-06-30","2026-02-01",1062,[408],"Mild Disabling Acute Ischemic Stroke",[389,410],"Control Group",{"trials":412,"activeCount":98},[],{"trials":414,"activeCount":98},[],{"intervention":410,"totalTrials":129,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":429,"NA":431},{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":129,"soonestReadout":403},[425],{"nctId":400,"briefTitle":401,"status":120,"phases":426,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":427,"interventions":428},[89],[408],[389,410],{"trials":430,"activeCount":98},[],{"trials":432,"activeCount":98},[],{"intervention":434,"totalTrials":31,"cells":435},"Chemotherapy",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":129,"soonestReadout":48},[442,454],{"nctId":443,"briefTitle":444,"status":110,"phases":445,"primaryCompletion":446,"completion":447,"start":448,"enrollment":170,"conditions":449,"interventions":452},"NCT03985891","The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer",[87,88],"2025-06-01","2026-06-01","2020-12-16",[450,451],"Colonic Neoplasms","Chemotherapy Effect",[453,434],"Anti-PD-1 Monoclonal Antibody JS001",{"nctId":46,"briefTitle":47,"status":120,"phases":455,"primaryCompletion":48,"completion":360,"start":456,"enrollment":457,"conditions":458,"interventions":460},[87,88],"2025-03-12",10,[459],"Pancreatic Cancer",[49,434],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"intervention":49,"totalTrials":129,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":470,"activeCount":98},[],{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":129,"soonestReadout":48},[475],{"nctId":46,"briefTitle":47,"status":120,"phases":476,"primaryCompletion":48,"completion":360,"start":456,"enrollment":457,"conditions":477,"interventions":478},[87,88],[459],[49,434],{"trials":480,"activeCount":98},[],{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[],{"intervention":486,"totalTrials":129,"cells":487},"nivolumab 4.5mg\u002Fkg+Paclitaxel (albumin-bound type) 260mg \u002F m2+ Carboplatin AUC5",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":129,"soonestReadout":499},[494],{"nctId":495,"briefTitle":496,"status":497,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":8,"conditions":502,"interventions":506},"NCT04699721","Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC","ACTIVE_NOT_RECRUITING",[88],"2027-09","2027-12","2020-07-01",[503,504,505],"Non-small Cell Lung Cancer Stage II","Non-small Cell Lung Cancer Stage ⅢA","Non-small Cell Lung Cancer Stage IIIB",[486],{"trials":508,"activeCount":98},[],{"trials":510,"activeCount":98},[],{"trials":512,"activeCount":98},[],{"intervention":74,"totalTrials":129,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":129,"soonestReadout":73},[519],{"nctId":71,"briefTitle":72,"status":520,"phases":521,"primaryCompletion":73,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":527},"ENROLLING_BY_INVITATION",[87],"2029-07-30","2025-07-10",20,[526],"Hepatocellular Carcinoma (HCC)",[74],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":98},[],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":98},[],{"intervention":54,"totalTrials":129,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":539,"activeCount":98},[],{"trials":541,"activeCount":98},[],{"trials":543,"activeCount":98},[],{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[],{"trials":549,"activeCount":129,"soonestReadout":53},[550],{"nctId":51,"briefTitle":52,"status":551,"phases":552,"primaryCompletion":53,"completion":73,"start":553,"enrollment":554,"conditions":555,"interventions":557},"RECRUITING",[91],"2023-02-01",258,[556],"Gastrointestinal Stromal Tumors",[54,558],"Sunitinib, Imatinib dosage, Dasatinib, Reveratinib",{"intervention":558,"totalTrials":129,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":571},{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":98},[],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[],{"trials":570,"activeCount":98},[],{"trials":572,"activeCount":129,"soonestReadout":53},[573],{"nctId":51,"briefTitle":52,"status":551,"phases":574,"primaryCompletion":53,"completion":73,"start":553,"enrollment":554,"conditions":575,"interventions":576},[91],[556],[54,558],{"intervention":578,"totalTrials":129,"cells":579},"Ivarmacitinib Sulfate",{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":98},[],{"trials":587,"activeCount":98},[],{"trials":589,"activeCount":98},[],{"trials":591,"activeCount":129,"soonestReadout":596},[592],{"nctId":593,"briefTitle":594,"status":120,"phases":595,"primaryCompletion":596,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":602},"NCT07276620","Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults",[91],"2028-04-30","2029-01-30","2025-11-30",1000,[601],"Atopic Dermatitis (AD)",[578],{"intervention":39,"totalTrials":129,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":98},[],{"trials":614,"activeCount":98},[],{"trials":616,"activeCount":129,"soonestReadout":38},[617],{"nctId":36,"briefTitle":37,"status":551,"phases":618,"primaryCompletion":38,"completion":167,"start":619,"enrollment":620,"conditions":621,"interventions":624},[],"2023-10-30",64,[622,623],"Leptomeningeal Metastasis","Lung Cancer",[39,39],{"intervention":84,"totalTrials":129,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[],{"trials":632,"activeCount":98},[],{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":129,"soonestReadout":83},[639],{"nctId":81,"briefTitle":82,"status":551,"phases":640,"primaryCompletion":83,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},[],"2029-05-25","2023-05-25",400,[645],"HBV",[84,647],"Nucleotide Analogues",{"intervention":647,"totalTrials":129,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":651,"activeCount":98},[],{"trials":653,"activeCount":98},[],{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"trials":659,"activeCount":98},[],{"trials":661,"activeCount":129,"soonestReadout":83},[662],{"nctId":81,"briefTitle":82,"status":551,"phases":663,"primaryCompletion":83,"completion":641,"start":642,"enrollment":643,"conditions":664,"interventions":665},[],[645],[84,647],{"intervention":667,"totalTrials":129,"cells":668},"Immunotherapy",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":98},[],{"trials":678,"activeCount":98},[],{"trials":680,"activeCount":129,"soonestReadout":685},[681],{"nctId":682,"briefTitle":683,"status":497,"phases":684,"primaryCompletion":685,"completion":686,"start":501,"enrollment":687,"conditions":688,"interventions":690},"NCT06243679","The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC",[],"2027-09-01","2027-12-01",100,[689],"Resectable\u002FPotentially Resectable NSCLC",[667],{"intervention":692,"totalTrials":31,"cells":693},"Sufentanil",{"EARLY_PHASE1":694,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":728},{"trials":695,"activeCount":98},[696],{"nctId":697,"briefTitle":698,"status":110,"phases":699,"primaryCompletion":700,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":707},"NCT03763084","Impact of Acetaminophen on Postoperative Delirium Elderly Patients After Non-cardiac Surgery",[86],"2020-02-01","2020-11-01","2019-02-15",164,[705,706],"Acetaminophen","Delirium in Old Age",[705,692],{"trials":709,"activeCount":98},[],{"trials":711,"activeCount":98},[],{"trials":713,"activeCount":98},[],{"trials":715,"activeCount":98},[716],{"nctId":717,"briefTitle":718,"status":110,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":725},"NCT03152955","Postoperative Analgesia in Patients With Microvascular Decompression",[90],"2018-05-15","2017-05-15",90,[724],"Trigeminal Neuralgia",[726,727,692],"Ketamine","ondansetron",{"trials":729,"activeCount":98},[],{"intervention":118,"totalTrials":31,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":757},{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[742,746],{"nctId":108,"briefTitle":109,"status":110,"phases":743,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":744,"interventions":745},[90],[116,18],[118,94],{"nctId":747,"briefTitle":748,"status":110,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":755},"NCT04006054","Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury",[90],"2021-06-30","2021-12-30","2019-06-06",82,[26],[756,118],"Dexmedetomidine",{"trials":758,"activeCount":98},[],{"intervention":760,"totalTrials":31,"cells":761},"Propofol",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":770,"NA":795},{"trials":763,"activeCount":98},[],{"trials":765,"activeCount":98},[],{"trials":767,"activeCount":98},[],{"trials":769,"activeCount":98},[],{"trials":771,"activeCount":98},[772,784],{"nctId":773,"briefTitle":774,"status":110,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT05325762","Effect of Propofol on Postoperative Sleep Quality in Elderly Patients With Sleep Disorders",[90],"2023-10-25","2023-12-25","2022-12-01",321,[781],"Sleep Disorder",[760,756,783],"Saline",{"nctId":785,"briefTitle":786,"status":110,"phases":787,"primaryCompletion":788,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":794},"NCT01708837","Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction",[90],"2014-01","2014-06","2012-10",300,[793],"Cognition Disorders",[760],{"trials":796,"activeCount":98},[],{"intervention":756,"totalTrials":31,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":805,"PHASE4":807,"NA":817},{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":98},[],{"trials":804,"activeCount":98},[],{"trials":806,"activeCount":98},[],{"trials":808,"activeCount":98},[809,813],{"nctId":773,"briefTitle":774,"status":110,"phases":810,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":811,"interventions":812},[90],[781],[760,756,783],{"nctId":747,"briefTitle":748,"status":110,"phases":814,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":815,"interventions":816},[90],[26],[756,118],{"trials":818,"activeCount":98},[],{"intervention":820,"totalTrials":129,"cells":821},"idebenone 30 mg for 14 days",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":842},{"trials":823,"activeCount":98},[],{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":98},[],{"trials":829,"activeCount":98},[],{"trials":831,"activeCount":98},[832],{"nctId":833,"briefTitle":834,"status":110,"phases":835,"primaryCompletion":360,"completion":360,"start":836,"enrollment":837,"conditions":838,"interventions":840},"NCT05987397","Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy",[90],"2023-07-05",2700,[839],"Post Stroke Epilepsy",[820,841],"idebenone 30 mg for 3 months",{"trials":843,"activeCount":98},[],{"intervention":841,"totalTrials":129,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":860},{"trials":847,"activeCount":98},[],{"trials":849,"activeCount":98},[],{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":98},[856],{"nctId":833,"briefTitle":834,"status":110,"phases":857,"primaryCompletion":360,"completion":360,"start":836,"enrollment":837,"conditions":858,"interventions":859},[90],[839],[820,841],{"trials":861,"activeCount":98},[],{"intervention":726,"totalTrials":129,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":878},{"trials":865,"activeCount":98},[],{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":98},[],{"trials":873,"activeCount":98},[874],{"nctId":717,"briefTitle":718,"status":110,"phases":875,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":876,"interventions":877},[90],[724],[726,727,692],{"trials":879,"activeCount":98},[],{"intervention":727,"totalTrials":129,"cells":881},{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":896},{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[],{"trials":891,"activeCount":98},[892],{"nctId":717,"briefTitle":718,"status":110,"phases":893,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":894,"interventions":895},[90],[724],[726,727,692],{"trials":897,"activeCount":98},[],{"intervention":899,"totalTrials":129,"cells":900},"Lacosamide 100 mg",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":909,"NA":921},{"trials":902,"activeCount":98},[],{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[911],{"nctId":912,"briefTitle":913,"status":110,"phases":914,"primaryCompletion":360,"completion":360,"start":836,"enrollment":915,"conditions":916,"interventions":919},"NCT05969054","Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy",[90],140,[917,918],"Alzheimer Disease 3","Epilepsy",[899,920],"Levetiracetam 250mg",{"trials":922,"activeCount":98},[],{"intervention":920,"totalTrials":129,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":939},{"trials":926,"activeCount":98},[],{"trials":928,"activeCount":98},[],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[935],{"nctId":912,"briefTitle":913,"status":110,"phases":936,"primaryCompletion":360,"completion":360,"start":836,"enrollment":915,"conditions":937,"interventions":938},[90],[917,918],[899,920],{"trials":940,"activeCount":98},[],{"intervention":942,"totalTrials":129,"cells":943},"Mescaline sodium enteric-coated",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":952,"NA":967},{"trials":945,"activeCount":98},[],{"trials":947,"activeCount":98},[],{"trials":949,"activeCount":98},[],{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[954],{"nctId":955,"briefTitle":956,"status":110,"phases":957,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":964},"NCT05933213","Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",[90],"2025-07","2025-12","2023-07-06",205,[963],"Lupus Nephritis",[942,965,966],"Morte-mescaline","Glucocorticoids",{"trials":968,"activeCount":98},[],{"intervention":965,"totalTrials":129,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":985},{"trials":972,"activeCount":98},[],{"trials":974,"activeCount":98},[],{"trials":976,"activeCount":98},[],{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[981],{"nctId":955,"briefTitle":956,"status":110,"phases":982,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":983,"interventions":984},[90],[963],[942,965,966],{"trials":986,"activeCount":98},[],{"intervention":966,"totalTrials":129,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":1003},{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[],{"trials":996,"activeCount":98},[],{"trials":998,"activeCount":98},[999],{"nctId":955,"briefTitle":956,"status":110,"phases":1000,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":1001,"interventions":1002},[90],[963],[942,965,966],{"trials":1004,"activeCount":98},[],{"intervention":783,"totalTrials":129,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1021},{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":98},[],{"trials":1014,"activeCount":98},[],{"trials":1016,"activeCount":98},[1017],{"nctId":773,"briefTitle":774,"status":110,"phases":1018,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":1019,"interventions":1020},[90],[781],[760,756,783],{"trials":1022,"activeCount":98},[],{"intervention":1024,"totalTrials":129,"cells":1025},"Anesthesia drugs during the surgery",{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1046},{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[],{"trials":1031,"activeCount":98},[],{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[1036],{"nctId":1037,"briefTitle":1038,"status":110,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":8,"conditions":1043,"interventions":1045},"NCT02727712","Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG",[90],"2016-09","2016-12","2016-04",[1044],"Coronary Heart Disease",[1024],{"trials":1047,"activeCount":98},[],{"intervention":1049,"totalTrials":129,"cells":1050},"Epalrestat,Mecobalamin",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1072},{"trials":1052,"activeCount":98},[],{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"trials":1060,"activeCount":98},[1061],{"nctId":1062,"briefTitle":1063,"status":110,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1070},"NCT05184049","Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients",[90],"2023-10","2022-01",72,[1069],"Diabetes",[1049,1071],"Mecobalamin",{"trials":1073,"activeCount":98},[],{"intervention":1071,"totalTrials":129,"cells":1075},{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1090},{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[1086],{"nctId":1062,"briefTitle":1063,"status":110,"phases":1087,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1088,"interventions":1089},[90],[1069],[1049,1071],{"trials":1091,"activeCount":98},[],{"intervention":1093,"totalTrials":19,"cells":1094},"Liraglutide",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1112,"PHASE4":1149,"NA":1151},{"trials":1096,"activeCount":98},[],{"trials":1098,"activeCount":98},[],{"trials":1100,"activeCount":98},[1101],{"nctId":1102,"briefTitle":1103,"status":1104,"phases":1105,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":98,"conditions":1109,"interventions":1110},"NCT04839237","The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients","WITHDRAWN",[88],"2020-12-01","2021-12-01","2017-12-01",[21],[1093,1111],"Liraglutide;metformin",{"trials":1113,"activeCount":98},[1114,1122,1129,1140],{"nctId":1115,"briefTitle":1116,"status":110,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":791,"conditions":1120,"interventions":1121},"NCT04487743","Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities",[89],"2022-06","2020-05-09",[21],[1093],{"nctId":1123,"briefTitle":1124,"status":110,"phases":1125,"primaryCompletion":1118,"completion":1118,"start":1126,"enrollment":791,"conditions":1127,"interventions":1128},"NCT04525300","Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities",[89],"2020-05-24",[21],[1093],{"nctId":1130,"briefTitle":1131,"status":110,"phases":1132,"primaryCompletion":1133,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1137},"NCT03671733","Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients",[89],"2022-09-01","2018-09-01",150,[21],[1093,1138,1139],"Exenatide","Exenatide Microspheres for",{"nctId":1141,"briefTitle":1142,"status":110,"phases":1143,"primaryCompletion":1144,"completion":1144,"start":1145,"enrollment":8,"conditions":1146,"interventions":1147},"NCT03986008","Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients",[89],"2021-12-23","2019-12-01",[21],[1148,1093],"Benaglutide",{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"intervention":1154,"totalTrials":129,"cells":1155},"metformin+empagliflozin+insulin glargine",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1175,"NA":1177},{"trials":1157,"activeCount":98},[],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[1164],{"nctId":1165,"briefTitle":1166,"status":110,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1133,"enrollment":1169,"conditions":1170,"interventions":1172},"NCT05545800","Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy",[89],"2024-06-01",78,[1171],"Type 2 Diabetes Mellitus",[1154,1173,1174],"IDegLira","premixed insulin analogues",{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[],{"intervention":1173,"totalTrials":129,"cells":1180},{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1193,"NA":1195},{"trials":1182,"activeCount":98},[],{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[1189],{"nctId":1165,"briefTitle":1166,"status":110,"phases":1190,"primaryCompletion":1168,"completion":1168,"start":1133,"enrollment":1169,"conditions":1191,"interventions":1192},[89],[1171],[1154,1173,1174],{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[],{"intervention":1174,"totalTrials":129,"cells":1198},{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1211,"NA":1213},{"trials":1200,"activeCount":98},[],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[1207],{"nctId":1165,"briefTitle":1166,"status":110,"phases":1208,"primaryCompletion":1168,"completion":1168,"start":1133,"enrollment":1169,"conditions":1209,"interventions":1210},[89],[1171],[1154,1173,1174],{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[],{"intervention":1138,"totalTrials":129,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1229,"NA":1231},{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[1225],{"nctId":1130,"briefTitle":1131,"status":110,"phases":1226,"primaryCompletion":1133,"completion":1133,"start":1134,"enrollment":1135,"conditions":1227,"interventions":1228},[89],[21],[1093,1138,1139],{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"intervention":1139,"totalTrials":129,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1241,"PHASE4":1247,"NA":1249},{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":98},[],{"trials":1242,"activeCount":98},[1243],{"nctId":1130,"briefTitle":1131,"status":110,"phases":1244,"primaryCompletion":1133,"completion":1133,"start":1134,"enrollment":1135,"conditions":1245,"interventions":1246},[89],[21],[1093,1138,1139],{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"intervention":1252,"totalTrials":129,"cells":1253},"Edaravone Dexborneol Concentrated Solution for",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1274,"NA":1276},{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[1262],{"nctId":1263,"briefTitle":1264,"status":110,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1272},"NCT05885919","Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke",[89],"2024-12-31","2023-07-01",212,[1270,1271],"Ischemic Stroke, Acute","Treatment Outcome",[1252,1273],"Edaravone Dexborneol placebo",{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"intervention":1273,"totalTrials":129,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1286,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[1288],{"nctId":1263,"briefTitle":1264,"status":110,"phases":1289,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":1268,"conditions":1290,"interventions":1291},[89],[1270,1271],[1252,1273],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"intervention":1148,"totalTrials":129,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1310,"NA":1312},{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[1306],{"nctId":1141,"briefTitle":1142,"status":110,"phases":1307,"primaryCompletion":1144,"completion":1144,"start":1145,"enrollment":8,"conditions":1308,"interventions":1309},[89],[21],[1148,1093],{"trials":1311,"activeCount":98},[],{"trials":1313,"activeCount":98},[],{"intervention":1315,"totalTrials":31,"cells":1316},"Toripalimab",{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[1323,1333],{"nctId":1324,"briefTitle":1325,"status":110,"phases":1326,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1332},"NCT03864211","Thermal Ablation Followed by Immunotherapy for HCC",[87,88],"2023-05-30","2019-06-15",145,[1331],"Hepatocellular Carcinoma Non-resectable",[1315],{"nctId":1334,"briefTitle":1335,"status":110,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":501,"enrollment":1339,"conditions":1340,"interventions":1341},"NCT05240404","Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma",[88],"2023-07-31","2024-07-31",116,[23],[1315],{"trials":1343,"activeCount":98},[],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"intervention":1349,"totalTrials":129,"cells":1350},"Neoadjuvant Chemotherapy",{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[1357],{"nctId":1358,"briefTitle":1359,"status":1360,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT02876861","Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC","COMPLETED",[88],"2022-08","2014-02",74,[1366],"High-Grade Upper Tract Urothelial Carcinoma",[1349],{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"intervention":1375,"totalTrials":129,"cells":1376},"Platinum-etoposide+Anlotinib",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[1383],{"nctId":1384,"briefTitle":1385,"status":110,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1393},"NCT04675697","Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer",[88],"2020-12-31","2021-01-31","2019-01-24",36,[1392],"Extensive-stage Small-cell Lung Cancer",[1375],{"trials":1395,"activeCount":98},[],{"trials":1397,"activeCount":98},[],{"trials":1399,"activeCount":98},[],{"intervention":1401,"totalTrials":129,"cells":1402},"sulforaphane",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[1409],{"nctId":1410,"briefTitle":1411,"status":110,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":722,"conditions":1415,"interventions":1417},"NCT04252261","Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage",[88],"2021-12-31","2020-06-01",[1416],"Frontal Lobe Dysfunction",[1401,1418],"placedo",{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":98},[],{"intervention":1418,"totalTrials":129,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1437,"PHASE4":1439,"NA":1441},{"trials":1428,"activeCount":98},[],{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[1433],{"nctId":1410,"briefTitle":1411,"status":110,"phases":1434,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":722,"conditions":1435,"interventions":1436},[88],[1416],[1401,1418],{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"intervention":1444,"totalTrials":129,"cells":1445},"D-TACE",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[1452],{"nctId":1453,"briefTitle":1454,"status":110,"phases":1455,"primaryCompletion":1387,"completion":1413,"start":1456,"enrollment":8,"conditions":1457,"interventions":1461},"NCT03881306","DEBOXA for Inoperable NET Liver Metastases",[87,88],"2018-07-01",[1458,1459,1460],"Neuroendocrine Tumors","Neoplasm Metastasis","Liver",[1444],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[],{"intervention":1469,"totalTrials":129,"cells":1470},"Naloxone",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":98},[],{"trials":1476,"activeCount":98},[1477],{"nctId":1478,"briefTitle":1479,"status":1360,"phases":1480,"primaryCompletion":1481,"completion":1482,"start":1483,"enrollment":1484,"conditions":1485,"interventions":1487},"NCT03751111","Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone",[87,88],"2019-03-01","2019-03-30","2019-02-13",126,[1486],"Chronic Pruritus",[1469],{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"intervention":1495,"totalTrials":129,"cells":1496},"Disitamab Vedotin combined with Sintilimab",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[],{"trials":1502,"activeCount":98},[1503],{"nctId":1504,"briefTitle":1505,"status":110,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1267,"enrollment":1508,"conditions":1509,"interventions":1511},"NCT05928897","Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab",[88],"2025-07-01",30,[1510],"Gastric Cancer",[1495],{"trials":1513,"activeCount":98},[],{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[],{"intervention":1519,"totalTrials":129,"cells":1520},"DNAzyme targeting EBV-LMP1",{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[],{"trials":1526,"activeCount":98},[1527],{"nctId":1528,"briefTitle":1529,"status":1360,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":170,"conditions":1534,"interventions":1535},"NCT01449942","Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma",[87,88],"2011-04","2011-09","2009-05",[28],[1519],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[],{"trials":1541,"activeCount":98},[],{"intervention":453,"totalTrials":129,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[1550],{"nctId":443,"briefTitle":444,"status":110,"phases":1551,"primaryCompletion":446,"completion":447,"start":448,"enrollment":170,"conditions":1552,"interventions":1553},[87,88],[450,451],[453,434],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"intervention":1561,"totalTrials":129,"cells":1562},"18F-AlF-NOTA-octreotide",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[1569],{"nctId":1570,"briefTitle":1571,"status":110,"phases":1572,"primaryCompletion":1573,"completion":1574,"start":1575,"enrollment":1576,"conditions":1577,"interventions":1579},"NCT03511768","A Study of 18F-AlF-NOTA-octreotide PET\u002FCT for Imaging Neuroendocrine Neoplasms",[87,88],"2019-12-30","2020-12-30","2018-01-02",65,[1578],"Neuroendocrine Neoplasm",[1561],{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[],{"trials":1585,"activeCount":98},[],{"intervention":1111,"totalTrials":129,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1598,"PHASE4":1600,"NA":1602},{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"trials":1593,"activeCount":98},[1594],{"nctId":1102,"briefTitle":1103,"status":1104,"phases":1595,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":98,"conditions":1596,"interventions":1597},[88],[21],[1093,1111],{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"trials":1603,"activeCount":98},[],{"intervention":1605,"totalTrials":129,"cells":1606},"18F-AlF-NOTA-neurotensin",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1608,"activeCount":98},[],{"trials":1610,"activeCount":98},[],{"trials":1612,"activeCount":98},[1613],{"nctId":1614,"briefTitle":1615,"status":110,"phases":1616,"primaryCompletion":1573,"completion":1574,"start":1617,"enrollment":1576,"conditions":1618,"interventions":1620},"NCT03516045","A Study of 18F-AlF-NOTA-Neurotensin PET\u002FCT for Imaging Prostate Cancer",[87,88],"2018-04-23",[1619],"Prostate Cancer",[1605],{"trials":1622,"activeCount":98},[],{"trials":1624,"activeCount":98},[],{"trials":1626,"activeCount":98},[],{"intervention":1628,"totalTrials":129,"cells":1629},"Peptide",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1646,"PHASE3":1648,"PHASE4":1650,"NA":1652},{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[1634],{"nctId":1635,"briefTitle":1636,"status":110,"phases":1637,"primaryCompletion":1638,"completion":1133,"start":1639,"enrollment":1508,"conditions":1640,"interventions":1642},"NCT04072900","A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma",[87],"2021-09-01","2020-04-21",[1641],"Melanoma (Skin)",[1628,1643,1644,1645],"Anti-PD-1","rhGM-CSF","Imiquimod 5% Topical Cream",{"trials":1647,"activeCount":98},[],{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":98},[],{"trials":1653,"activeCount":98},[],{"intervention":1643,"totalTrials":129,"cells":1655},{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1670},{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[1660],{"nctId":1635,"briefTitle":1636,"status":110,"phases":1661,"primaryCompletion":1638,"completion":1133,"start":1639,"enrollment":1508,"conditions":1662,"interventions":1663},[87],[1641],[1628,1643,1644,1645],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[],{"trials":1671,"activeCount":98},[],{"intervention":1644,"totalTrials":129,"cells":1673},{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":98},[1678],{"nctId":1635,"briefTitle":1636,"status":110,"phases":1679,"primaryCompletion":1638,"completion":1133,"start":1639,"enrollment":1508,"conditions":1680,"interventions":1681},[87],[1641],[1628,1643,1644,1645],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"intervention":1645,"totalTrials":129,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1693,"activeCount":98},[],{"trials":1695,"activeCount":98},[1696],{"nctId":1635,"briefTitle":1636,"status":110,"phases":1697,"primaryCompletion":1638,"completion":1133,"start":1639,"enrollment":1508,"conditions":1698,"interventions":1699},[87],[1641],[1628,1643,1644,1645],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"intervention":1709,"totalTrials":129,"cells":1710},"Digoxin",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1712,"activeCount":98},[],{"trials":1714,"activeCount":98},[1715],{"nctId":1716,"briefTitle":1717,"status":1360,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":114,"conditions":1721,"interventions":1723},"NCT06546215","Bioequivalence Study of Digoxin Tablet in Healthy Subjects",[87],"2021-01-23","2020-07-05",[1722],"Heart Failure",[1709],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[],{"intervention":1733,"totalTrials":129,"cells":1734},"Gemcitabine",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[1739],{"nctId":1740,"briefTitle":1741,"status":1360,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":1745,"conditions":1746,"interventions":1747},"NCT03876574","Hepatic Artery Infusion Pump for NPC Liver Metastases",[87],"2017-12-31","2011-01-01",16,[28,1459,1460],[1733,1748,1749],"Floxuridine","dexamethasone",{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"intervention":1748,"totalTrials":129,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[1764],{"nctId":1740,"briefTitle":1741,"status":1360,"phases":1765,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":1745,"conditions":1766,"interventions":1767},[87],[28,1459,1460],[1733,1748,1749],{"trials":1769,"activeCount":98},[],{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"trials":1775,"activeCount":98},[],{"intervention":1749,"totalTrials":129,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[1782],{"nctId":1740,"briefTitle":1741,"status":1360,"phases":1783,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":1745,"conditions":1784,"interventions":1785},[87],[28,1459,1460],[1733,1748,1749],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"intervention":705,"totalTrials":129,"cells":1795},{"EARLY_PHASE1":1796,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1797,"activeCount":98},[1798],{"nctId":697,"briefTitle":698,"status":110,"phases":1799,"primaryCompletion":700,"completion":701,"start":702,"enrollment":703,"conditions":1800,"interventions":1801},[86],[705,706],[705,692],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[],{"trials":1809,"activeCount":98},[],{"trials":1811,"activeCount":98},[],{"intervention":1813,"totalTrials":129,"cells":1814},"Diprivan",{"EARLY_PHASE1":1815,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1816,"activeCount":98},[1817],{"nctId":1818,"briefTitle":1819,"status":110,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":114,"conditions":1823,"interventions":1825},"NCT02972762","Anesthesia Depth's Influence on Postoperative Delirium",[86],"2018-12","2016-11",[1824],"Femur Head Necrosis",[1813],{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":98},[],{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"intervention":1837,"totalTrials":129,"cells":1838},"Cardunilizumab",{"EARLY_PHASE1":1839,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1840,"activeCount":98},[1841],{"nctId":1842,"briefTitle":1843,"status":110,"phases":1844,"primaryCompletion":1845,"completion":210,"start":1846,"enrollment":1847,"conditions":1848,"interventions":1850},"NCT06114173","Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma",[86],"2023-06-30","2022-11-01",15,[1849],"Sarcoma, Soft Tissue",[1837],{"trials":1852,"activeCount":98},[],{"trials":1854,"activeCount":98},[],{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[],{"intervention":1862,"totalTrials":129,"cells":1863},"Entacapone",{"EARLY_PHASE1":1864,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1884},{"trials":1865,"activeCount":98},[1866],{"nctId":1867,"briefTitle":1868,"status":1360,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":19,"conditions":1872,"interventions":1874},"NCT04006769","Entacapone Combination With Imatinib for Treatment of GIST",[86],"2022-08-31","2020-10-30",[1873],"Gastrointestinal Stromal Tumor, Malignant",[1862,1875],"Imatinib Mesylate",{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[],{"intervention":1875,"totalTrials":129,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1889,"activeCount":98},[1890],{"nctId":1867,"briefTitle":1868,"status":1360,"phases":1891,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":19,"conditions":1892,"interventions":1893},[86],[1873],[1862,1875],{"trials":1895,"activeCount":98},[],{"trials":1897,"activeCount":98},[],{"trials":1899,"activeCount":98},[],{"trials":1901,"activeCount":98},[],{"trials":1903,"activeCount":98},[],{"intervention":1905,"totalTrials":129,"cells":1906},"BBM-P002",{"EARLY_PHASE1":1907,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1908,"activeCount":98},[1909],{"nctId":1910,"briefTitle":1911,"status":1360,"phases":1912,"primaryCompletion":1913,"completion":1913,"start":1914,"enrollment":457,"conditions":1915,"interventions":1917},"NCT05822739","Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)",[86],"2025-10-30","2023-04-14",[1916],"Parkinson's Disease",[1905],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"trials":1925,"activeCount":98},[],{"trials":1927,"activeCount":98},[],{"intervention":1929,"totalTrials":129,"cells":1930},"Sodium Bicarbonate Ringer's Solution",{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[],{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[1943],{"nctId":1944,"briefTitle":1945,"status":110,"phases":1946,"primaryCompletion":1947,"completion":1948,"start":1949,"enrollment":1950,"conditions":1951,"interventions":1953},"NCT04621981","Sodium Bicarbonate Ringer's Solution Versus Normal Saline for Early Fluid Resuscitation in Patients With Sepsis",[91],"2022-09-30","2022-12-30","2021-03-11",450,[1952],"Sepsis, Septic Shock",[1929,1954],"Normal Saline",{"intervention":1954,"totalTrials":129,"cells":1956},{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[1969],{"nctId":1944,"briefTitle":1945,"status":110,"phases":1970,"primaryCompletion":1947,"completion":1948,"start":1949,"enrollment":1950,"conditions":1971,"interventions":1972},[91],[1952],[1929,1954],{"intervention":1974,"totalTrials":129,"cells":1975},"Triamcinolone acetonide",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[1988],{"nctId":1989,"briefTitle":1990,"status":110,"phases":1991,"primaryCompletion":1992,"completion":1338,"start":1993,"enrollment":524,"conditions":1994,"interventions":2001},"NCT05488860","Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases",[91],"2024-06-30","2022-07-30",[1995,1996,1997,1998,1999,2000],"Skin Diseases","Hypertrophic Scar","Keloid","Plantar Wart","Warts","Skin Tumor",[1974,2002],"5-ALA (a photosensitizer for photodynamic therapy).",{"intervention":2002,"totalTrials":129,"cells":2004},{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[],{"trials":2010,"activeCount":98},[],{"trials":2012,"activeCount":98},[],{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[2017],{"nctId":1989,"briefTitle":1990,"status":110,"phases":2018,"primaryCompletion":1992,"completion":1338,"start":1993,"enrollment":524,"conditions":2019,"interventions":2020},[91],[1995,1996,1997,1998,1999,2000],[1974,2002],{"intervention":2022,"totalTrials":129,"cells":2023},"tenofovir alafenamide",{"EARLY_PHASE1":2024,"PHASE1":2026,"PHASE2":2028,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[2036],{"nctId":2037,"briefTitle":2038,"status":1360,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":2042,"conditions":2043,"interventions":2045},"NCT05453448","The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study",[91],"2022-05-30","2022-05-01",272,[2044],"Antiviral Drugs",[2022,2046],"Entecavir",{"intervention":2046,"totalTrials":129,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":98},[],{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[],{"trials":2060,"activeCount":98},[2061],{"nctId":2037,"briefTitle":2038,"status":1360,"phases":2062,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":2042,"conditions":2063,"interventions":2064},[91],[2044],[2022,2046],{"intervention":2066,"totalTrials":129,"cells":2067},"Methylene Blue",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2069,"activeCount":98},[],{"trials":2071,"activeCount":98},[],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"trials":2079,"activeCount":98},[2080],{"nctId":2081,"briefTitle":2082,"status":110,"phases":2083,"primaryCompletion":1845,"completion":2084,"start":2085,"enrollment":2086,"conditions":2087,"interventions":2089},"NCT04970602","The Effect of Early Use of Methylene Blue on Hemodynamics in Septic Shock",[91],"2024-01-01","2021-06-20",106,[2088],"Septic Shock",[2066],{"intervention":2091,"totalTrials":129,"cells":2092},"The compound methyl salicylate liniment",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2101,"NA":2103},{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":98},[],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[2105],{"nctId":2106,"briefTitle":2107,"status":1360,"phases":2108,"primaryCompletion":112,"completion":112,"start":113,"enrollment":2109,"conditions":2110,"interventions":2112},"NCT05489939","Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China",[],3600,[2111],"Pain",[2091],{"intervention":2114,"totalTrials":129,"cells":2115},"Meropenem，Imipenem，Caspofene，Osstat",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[2128],{"nctId":2129,"briefTitle":2130,"status":110,"phases":2131,"primaryCompletion":1145,"completion":1145,"start":2132,"enrollment":643,"conditions":2133,"interventions":2136},"NCT03884881","Second-generation Sequencing Guides the Treatment of Severe Pneumonia",[91],"2018-01-01",[2134,2135],"Pneumonia","Metagenomic Next Generation Sequencing",[2114]]